Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

NCT03896984 · clinicaltrials.gov ↗

COMPLETED

Status

346

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Radium-223 (Xofigo, BAY88-8223)
DRUG: Abiraterone
DRUG: Enzalutamide

Sponsor

Bayer